Coronary intervention in patients with acute coronary syndrome: does every culprit lesion require revascularization?
In patients presenting with acute coronary syndromes, 30-60% of patients have multiple significant coronary lesions. Patients presenting with acute coronary syndrome and multivessel disease have a significant increase in the incidence of major cardiovascular morbidity and mortality when compared with patients who have single-vessel disease. Although great progress has been made to reduce the extent of infarction through effective and rapid reperfusion due to faster time to reperfusion, potent antiplatelets, and antithrombotics, there is not much consensus as to how best to treat multivessel disease in patients presenting with acute coronary syndromes. We present a review of the current body of evidence for safety and efficacy of multivessel revascularization in patients presenting with acute coronary syndromes.
Bangalore
Sripal
S
Division of Cardiology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 0BC3-Room 012P, 1620 Tremont Street, Boston, MA 02120, USA.
Faxon
David P
DP
D054058:Acute Coronary Syndrome / Q000188:drug therapy / Q000473:pathology / Q000601:surgery / Q000628:therapy*; D000800:Angioplasty, Balloon; D001026:Coronary Artery Bypass; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D012307:Risk Factors; D040242:Risk Reduction Behavior; D012720:Severity of Illness Index
D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors